

TITLE: NEW APPROACH FOR OSTEOARTHRITIS TREATMENT

FIELD OF INTEREST

Biotechnology, Pharma (Bone, Natural compounds)

CLINICAL NEED

Overexpression of collagen X and alkaline phosphatase as well as chondrocyte mineralization play an important role in the onset of Osteoarthritis. The inhibition or delay of both processes in pre-chondrocyte cells is a landmark of first magnitude when inhibiting the osteoarthritic process.

The prevention of progressive calcification in the deep layers of hyaline cartilage and the prevention of subchondral bone sclerosis are two therapeutic goals in the development of new drugs in the field of osteoarthritis. Currently, there is no known clinical drug capable of modifying the natural course of the disease.

DESCRIPTION OF THE INVENTION

The present invention would significantly improve the quality of life and reduce the dependency levels of the osteoarthritic patient by addressing the onset and progression of the disease. It demonstrates the regenerative capacity on cartilage chondrocytes, taking advantage of the anti-hypertrophic properties of the molecule.

TECHNOLOGY KEYWORDS

Osteoarthritis, Parathormone (PTHrP), Hypertrophic, Chondrocytes, Calcification, Collagen X, Alkaline phosphatase.

IPR STATUS

Patent application number: P201531318.

Applicant: IIS-FJD.

TYPE AND ROLE OF PARTNER

Looking for technological partners for going through clinical trials as well as commercial partners interested in licensing.

Contact details:

Innovation Unit
e-mail: irene.ruano@fjd.es
Phone number: 0034-915504800 Ext.3455